Dermatology pharma selling Zoryve, a topical treatment for psoriasis, eczema and seborrheic dermatitis.
Dermatology pharma selling Zoryve, a topical treatment for psoriasis, eczema and seborrheic dermatitis.
Rests almost entirely on Zoryve, sold in the US through wholesalers and pharmacies and paid for by insurers and pharmacy-benefit managers, the intermediaries that decide how easily patients can get it. Sales therefore depend on insurance coverage and on persuading doctors to prescribe a newer topical drug.
Moat: narrow (IP / patents). Zoryve's steroid-free mechanism and patents differentiate it from generic topical steroids.
Headquarters: Westlake Village, California, US · Founded: 2016 · Employees: 354
Size Arcutis Biotherapeutics (ARQT) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $3.49B, the 1435th largest of 3,085 United States companies the cockpit tracks. Shares closed at $27.61 on 18 Nov 2026.
Performance Over six months the shares gained 34.9%, against +3.4% for the median peer and -2.2% for the United States market (cap-weighted) — 6th highest of 20 in its peer set.
Growth Revenue grew 60.0% over the last twelve months (peer median +7.9%); the operating margin is 6.9% (peer median 12.2%).
Valuation It trades at 41.0× forward earnings against a peer median of 16.8× (3rd most expensive of 12).
Price implies For today's price to make sense, revenue must grow about 49% a year for seven years (Req g). Recent delivered growth is +367%, so the hurdle is -318 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 12.6 points above its cost of capital (13.1% WACC).
Short interest Short interest is 14.4% of the free float (30 Oct 2026).
Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $509M | $376M | $197M | $59.6M | $3.69M |
| Revenue growth | — | +91% | +230% | +1,517% | — |
| Gross profit | $464M | $339M | $177M | $53.5M | $1.99M |
| EBITDA | $38.1M | -$6.86M | -$126M | -$239M | -$300M |
| Net income | $29.9M | -$16.1M | -$140M | -$262M | -$311M |
| Free cash flow | $59.7M | -$6.31M | -$112M | -$247M | -$258M |
| Capital expenditure | $255,000 | $10.7M | $5.14M | $428,000 | $7.83M |
| Total debt | $124M | $114M | $111M | $206M | $203M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Arcutis Biotherapeutics ARQT | $3.49B | +35% | +60% | 7% | 41.0× | 49.2% |
| Incyte INCY | $24.0B | +21% | +25% | 12% | 15.1× | 14.2% |
| Pfizer PFE | $160B | +9% | +1% | 26% | 9.9× | -4.3% |
| Organon & OGN | $3.66B | +3% | -3% | 20% | 4.0× | -4.1% |
| Galderma GALD.SW | $51.9B | +18% | +16% | 19% | 45.7× | 18.0% |
| Sanofi SAN.PA | $114B | +13% | +15% | 27% | 9.7× | -4.8% |
| AbbVie ABBV | $506B | +35% | +11% | 36% | 18.1× | -0.1% |
| Lilly (Eli) LLY | $1.30T | +36% | +46% | 51% | 29.5× | 6.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ARQT | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -15.9% | +4.5% | 2nd lowest of 21 |
| 6-month return | +34.9% | +3.4% | 6th highest of 20 |
| Distance from 52-week high | -20.7% | -20.9% | 11th highest of 21 |
| Revenue growth (TTM) | +60.0% | +7.9% | 3rd highest of 18 |
| Operating margin | 6.9% | 12.2% | 7th lowest of 16 |
| Forward P/E | 41.0× | 16.8× | 3rd most expensive of 12 |
| Growth the price implies (Req g, 7 yrs) | 49.2% | -2.8% | 2nd most demanding of 11 |
| Growth delivered (Del g) | +367.3% | +5.6% | highest of 11 |
| Hurdle (Req g minus delivered) | -318.1 pp | -10.8 pp | least demanding of 11 |
| ROIC minus cost of capital | +12.6 pp | +3.7 pp | 3rd highest of 16 |
| EV / EBITDA | 88.0× | 12.1× | most expensive of 8 |
| Net debt / EBITDA | -3.6× | 2.6× | least indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Arcutis Biotherapeutics ARQT | United States | $3.49B | +35% | +60% | 7% | 41.0× | 49.2% | +367.3% |
| Shanghai Junshi Biosciences 1877.HK | Hong Kong | $3.49B | -38% | +36% | -14% | n/a | n/a | n/a |
| Acutaas Chemicals ACUTAAS.NS | India | $3.50B | +38% | +45% | 36% | 63.6× | n/a | n/a |
| Jiangsu Nhwa Pharmaceutical 002262.SZ | China | $3.48B | +8% | +3% | 19% | 19.6× | -2.1% | +12.0% |
| Siegfried SFZN.SW | Switzerland | $3.51B | -17% | +4% | 16% | 16.8× | n/a | n/a |
| Parabilis Medicines PBLS | United States | $3.52B | n/a | n/a | n/a | n/a | n/a | n/a |
| Wockhardt WOCKPHARMA.NS | India | $3.52B | +25% | +26% | 13% | n/a | 58.0% | +4.2% |
| Amylyx Pharmaceuticals AMLX | United States | $3.42B | +93% | +100% | n/a | n/a | n/a | n/a |
| Viridian Therapeutics VRDN | United States | $3.42B | +71% | -63% | -1,781% | n/a | n/a | n/a |
| Simcere Pharmaceutical 2096.HK | Hong Kong | $3.42B | -5% | +27% | 18% | 13.5× | -3.4% | +10.6% |
| Piramal Pharma PPLPHARMA.NS | India | $3.40B | +38% | +9% | 3% | 150.8× | n/a | n/a |
| China Resources Pharmaceutical 3320.HK | Hong Kong | $3.60B | -7% | +8% | 4% | 5.8× | -4.9% | +7.8% |
| Zhejiang Huahai Pharmaceutical 600521.SS | China | $3.61B | 0% | +10% | 12% | 20.1× | 6.4% | +5.9% |
| Apeloa Pharmaceutical 000739.SZ | China | $3.37B | +17% | -16% | 10% | 22.9× | 4.7% | +4.5% |
| Viking Therapeutics VKTX | United States | $3.34B | -9% | n/a | n/a | n/a | n/a | n/a |
| Organon & OGN | United States | $3.66B | +3% | -3% | 20% | 4.0× | -4.1% | -1.0% |
| SELLAS Life Sciences SLS | United States | $3.66B | +100% | n/a | n/a | n/a | n/a | n/a |
| Xenon Pharmaceuticals XENE | United States | $3.71B | -31% | -100% | n/a | n/a | n/a | n/a |
| Livzon Pharmaceutical 1513.HK | Hong Kong | $3.73B | -9% | -10% | 19% | 11.3× | -7.0% | +2.0% |
| China National Medicines 600511.SS | China | $3.26B | +3% | +3% | 4% | 10.5× | -10.0% | +5.4% |
| Tarsus Pharmaceuticals TARS | United States | $3.74B | +17% | +86% | -10% | n/a | 34.7% | +159.5% |